Abstract
Trabectedin therapy was prescribed for a patient with radiation-induced sarcoma. Two doses of trabectedin were given before therapy was discontinued with the patient experiencing renal and liver failure. Despite discontinuing trabectedin the patient continued to experience increases in liver transaminases, bilirubin, blood urea nitrogen, and serum creatinine. Hemodialysis was initiated with no improvement. With all other causes being ruled out, trabectedin likely caused hepatic and renal failure leading to death in this patient. Recent literature suggests that patients may benefit from prophylactic dexamethasone as a means of reducing hepatic toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 269-272 |
| Number of pages | 4 |
| Journal | Journal of Oncology Pharmacy Practice |
| Volume | 16 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pharmacology (medical)
Cite this
Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma. / Pick, Amy; Nystrom, Kelly K.
In: Journal of Oncology Pharmacy Practice, Vol. 16, No. 4, 12.2010, p. 269-272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma
AU - Pick, Amy
AU - Nystrom, Kelly K.
PY - 2010/12
Y1 - 2010/12
N2 - Trabectedin therapy was prescribed for a patient with radiation-induced sarcoma. Two doses of trabectedin were given before therapy was discontinued with the patient experiencing renal and liver failure. Despite discontinuing trabectedin the patient continued to experience increases in liver transaminases, bilirubin, blood urea nitrogen, and serum creatinine. Hemodialysis was initiated with no improvement. With all other causes being ruled out, trabectedin likely caused hepatic and renal failure leading to death in this patient. Recent literature suggests that patients may benefit from prophylactic dexamethasone as a means of reducing hepatic toxicity.
AB - Trabectedin therapy was prescribed for a patient with radiation-induced sarcoma. Two doses of trabectedin were given before therapy was discontinued with the patient experiencing renal and liver failure. Despite discontinuing trabectedin the patient continued to experience increases in liver transaminases, bilirubin, blood urea nitrogen, and serum creatinine. Hemodialysis was initiated with no improvement. With all other causes being ruled out, trabectedin likely caused hepatic and renal failure leading to death in this patient. Recent literature suggests that patients may benefit from prophylactic dexamethasone as a means of reducing hepatic toxicity.
UR - http://www.scopus.com/inward/record.url?scp=78650444420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650444420&partnerID=8YFLogxK
U2 - 10.1177/1078155209352821
DO - 10.1177/1078155209352821
M3 - Article
C2 - 20015930
AN - SCOPUS:78650444420
VL - 16
SP - 269
EP - 272
JO - Journal of Oncology Pharmacy Practice
JF - Journal of Oncology Pharmacy Practice
SN - 1078-1552
IS - 4
ER -